Norway (NO)

Autotaxin activity predicts transplant-free survival in primary sclerosing cholangitis (2019) Dhillon AK, Kremer A, Kummen M, Boberg KM, Elferink RP, Karlsen TH, Beuers U, et al. Journal article Influence of Antisynthetase Antibodies Specificities on Antisynthetase Syndrome Clinical Spectrum Time Course (2019) Cavagna L, Trallero-Araguas E, Meloni F, Cavazzana I, Rojas-Serrano J, Feist E, Zanframundo G, et al. Journal article Imaging in ESC clinical guidelines: chronic coronary syndromes (2019) Saraste A, Barbato E, Capodanno D, Edvardsen T, Prescott E, Achenbach S, Bax JJ, et al. Journal article Setting behavior and bioactivity assessment of calcium carbonate cements (2019) Rodríguez-Sánchez J, Myszka B, Boccaccini AR, Dysthe DK Journal article Opinion of the Scientific Committee on Consumer safety (SCCS) – Opinion on the safety of cosmetic ingredient salicylic acid (CAS 69-72-7) (2019) Panteri E, Bernauer U, Bodin L, Chaudhry Q, Coenraads P, Dusinska M, Ezendam J, et al. Journal article CTCF variants in 31 individuals with a variable neurodevelopmental disorder broaden the mutational and clinical spectrum (2019) Konrad E, Nardini N, Blyth M, Prescott K, Bouman AM, Brilstra EH, Caliebe A, et al. Conference contribution Opinion of the Scientific Committee on Consumer safety (SCCS) - Opinion on Ethylzingerone - 'Hydroxyethoxyphenyl Butanone' (HEPB) - Cosmetics Europe No P98-CAS No 569646-79-3-Submission II (eye irritation) (2019) Bernauer U, Bodin L, Chaudhry Q, Coenraads P, Dusinska M, Ezendam J, Gaffet E, et al. Journal article, Editorial Opinion of the Scientific Committee on consumer safety (SCCS) - Final opinion on the safety of fragrance ingredient Acetylated Vetiver Oil (AVO) - (Vetiveria zizanioides root extract acetylated) - Submission III (2019) Bernauer U, Bodin L, Chaudhry Q, Coenraads P, Dusinska M, Ezendam J, Gaffet E, et al. Journal article, Editorial Efficacy and Safety of Nintedanib in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease by Use of Mycophenolate at Baseline: Subgroup Analysis of the SENSCIS Trial (2019) Highland K, Distler O, Kuwana M, Allanore Y, Assassi S, Azuma A, Bourdin A, et al. Conference contribution The INBUILD Trial of Nintedanib in Patients with Progressive Fibrosing Interstitial Lung Diseases: Subgroup with Autoimmune Diseases (2019) Matteson E, Kelly C, Distler J, Mann-Vold AMH, Seibold J, Mittoo S, Distler O, et al. Conference contribution